Significant Ownership of Avidity Partners Management LP
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for Avidity Partners Management LP focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- By: Avidity Partners Management (GP) LLC, its general partner, /s/ Michael Gregory - Michael Gregory, Managing Member
- Manager location
- Dallas, TX
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow Avidity Partners Management LP with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from Avidity Partners Management LP
Significant Ownership of Avidity Partners Management LP
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IMUX | Immunic, Inc. | Common Stock, $0.0001 par value | 9.9% | $15,493,835 | +$10,277,489 | 13,958,410 | +197% | Avidity Partners Management LP | 17 Feb 2026 |
| SCYX | Scynexis, Inc. | Common Stock, par value $0.001 per share | 9.9% | $2,921,533 | -$59,527 | 4,426,565 | -2% | Avidity Partners Management LP | 31 Dec 2025 |
| CNTX | Context Therapeutics Inc. | Common Stock, par value $0.001 per share | 8.7% | $21,753,357 | -$2,352,163 | 8,302,808 | -9.8% | Avidity Partners Management LP | 31 Mar 2026 |
| SYRS | Syros Pharmaceuticals, Inc. | Common Stock, $0.001 par value | 7.6% | $61,441 | 2,048,020 | Avidity Partners Management LP | 31 Dec 2024 | ||
| KZR | Kezar Life Sciences, Inc. | Common Stock, par value $0.001 per share | 6.9% | $397,054 | 502,600 | Avidity Partners Management LP | 31 Dec 2024 | ||
| CATX | Perspective Therapeutics, Inc. | Common Stock, $0.001 par value | 5.3% | $29,523,995 | +$15,659,798 | 6,049,999 | +113% | Avidity Partners Management LP | 20 Feb 2026 |
| DNTH | Dianthus Therapeutics, Inc. | Common Stock, $0.001 par value | 4.9% | $70,995,168 | -$43,010,234 | 2,104,184 | -38% | Avidity Partners Management LP | 17 Nov 2025 |
| KZR | Kezar Life Sciences, Inc. | Common Stock, par value $0.001 per share | 0% | $0 | 0 | Avidity Partners Management LP | 30 Sep 2025 |
Schedules 13D/G Reported by Avidity Partners Management LP:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.